prikaz prve stranice dokumenta The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
  Preuzmi
PDF 1.03 MB
Znanstveni rad - Izvorni znanstveni rad
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
Frontiers in Pharmacology, 11 (2021); 591134. https://doi.org/10.3389/fphar.2020.591134
Moorkens, Evelien; Godman, Brian; Huys, Isabelle; Hoxha, Iris; Malaj, Admir; Keuerleber, Simon; Stockinger, Silvia; Mörtenhuber, Sarah; Dimitrova, Maria; Tachkov, Konstantin; Vončina, Luka; Vlahović-Palčevski, Vera; Achniotou, Gnosia; Slabý, Juraj; Popelková, Leona; Kohoutová, Kateřina; Bartels, Dorthe; Laius, Ott; Martikainen, Jaana E.; Selke, Gisbert W.; Kourafalos, Vasileios; Magnússon, Einar; Einarsdóttir, Rannveig; Adams, Roisín; Joppi, Roberta; Allocati, Eleonora; Jakupi, Arianit; Viksna, Anita; Greičiūtė-Kuprijanov, Ieva; Vella Bonanno, Patricia; Suttorp, Vincent; Melien, Øyvind; Plisko, Robert; Mardare, Ileana; Meshkov, Dmitry; Novakovic, Tanja; Fürst, Jurij; Zara, Corinne; Marković-Peković, Vanda; Grubiša, Nataša; Befrits, Gustaf; Puckett, Robert; Vulto, Arnold G. Više autora...

Citiranost:
,
Citirajte ovaj rad

Moorkens, E., Godman, B., Huys, I., Hoxha, I., Malaj, A., Keuerleber, S. ... Vulto, A. G. (2021). The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Frontiers in Pharmacology, 11.. doi: 10.3389/fphar.2020.591134

Moorkens, Evelien, et al. "The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures." Frontiers in Pharmacology, vol. 11, 2021. https://doi.org/10.3389/fphar.2020.591134

Moorkens, Evelien, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Simon Keuerleber, Silvia Stockinger, et al. "The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures." Frontiers in Pharmacology 11 (2021). https://doi.org/10.3389/fphar.2020.591134

Moorkens, E., et al. (2021) 'The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures', Frontiers in Pharmacology, 11. doi: 10.3389/fphar.2020.591134

Moorkens E, Godman B, Huys I, Hoxha I, Malaj A, Keuerleber S, i sur.. The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Frontiers in Pharmacology [Internet]. 2021. [pristupljeno 25.02.2025.];11. doi: 10.3389/fphar.2020.591134

E. Moorkens, et al., "The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures", Frontiers in Pharmacology, vol. 11, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:267790. [Citirano: 25.02.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:267790
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
AutorEvelien Moorkens
AutorBrian Godman
AutorIsabelle Huys
AutorIris Hoxha
AutorAdmir Malaj
AutorSimon Keuerleber
AutorSilvia Stockinger
AutorSarah Mörtenhuber
AutorMaria Dimitrova
AutorKonstantin Tachkov
AutorLuka Vončina
AutorVera Vlahović-Palčevski
AutorGnosia Achniotou
AutorJuraj Slabý
AutorLeona Popelková
AutorKateřina Kohoutová
AutorDorthe Bartels
AutorOtt Laius
AutorJaana E. Martikainen
AutorGisbert W. Selke
AutorVasileios Kourafalos
AutorEinar Magnússon
AutorRannveig Einarsdóttir
AutorRoisín Adams
AutorRoberta Joppi
AutorEleonora Allocati
AutorArianit Jakupi
AutorAnita Viksna
AutorIeva Greičiūtė-Kuprijanov
AutorPatricia Vella Bonanno
AutorVincent Suttorp
AutorØyvind Melien
AutorRobert Plisko
AutorIleana Mardare
AutorDmitry Meshkov
AutorTanja Novakovic
AutorJurij Fürst
AutorCorinne Zara
AutorVanda Marković-Peković
AutorNataša Grubiša
AutorGustaf Befrits
AutorRobert Puckett
AutorArnold G. Vulto
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za farmakologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Klinička farmakologija s toksikologijom
Sažetak (engleski)
From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry. The aim of this paper is to provide a European overview of (list) prices of originator adalimumab, before and after loss of exclusivity; to report changes in the reimbursement status of adalimumab products; and discuss... Više relevant policy measures. Experts in European countries received a survey consisting of three parts: 1) general financing/co-payment of medicines, 2) reimbursement status and prices of originator adalimumab, and availability of biosimilars, and 3) policy measures related to the use of adalimumab. In May 2019, adalimumab biosimilars were available in 24 of the 30 countries surveyed. Following introduction of adalimumab biosimilars, a number of countries have made changes in relation to the reimbursement status of adalimumab products. Originator adalimumab list prices varied between countries by a factor of 2.8 before and 4.1 after loss of exclusivity. Overall, list prices of originator adalimumab decreased after loss of exclusivity, although for 13 countries list prices were unchanged. When reported, discounts/rebates on originator adalimumab after loss of exclusivity ranged from 0% to approximately 26% (Romania), 60% (Poland), 80% (Denmark, Italy, Norway), and 80–90% (Netherlands), leading to actual prices per pen or syringe between €412 (Finland) and €50 – €99 (Netherlands). To leverage competition following entry of biosimilar adalimumab, only a few countries adopted measures specifically for adalimumab in addition to general policies regarding biosimilars. In some countries, a strategy was implemented even before loss of exclusivity (Denmark, Scotland), while others did not report specific measures. Even though originator adalimumab is the highest selling product in the world, few countries have implemented specific policies and practices for (biosimilar) adalimumab. Countries with biosimilars on the market seem to have competition lowering list or actual prices. Reported discounts varied widely between countries. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFrontiers in Pharmacology
Brojčani podacivol. 11, 591134
e-ISSN1663-9812
DOIhttps://doi.org/10.3389/fphar.2020.591134
URN:NBNurn:nbn:hr:184:267790
Datum objave publikacije2021
URL dokumentahttps://www.frontiersin.org/articles/10.3389/fphar.2020.591134/full
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2021-02-18 20:43:46
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.